Aim: Liver steatosis frequently occurs following liver transplantation (LT) and can affect patient outcome. Here, we aimed to clarify the steatosis and steatohepatitis risk factors that apply after living-donor LT for chronic hepatitis C.
INTRODUCTION

D
UE TO ADVANCES in surgical techniques and immunosuppressive therapy, liver transplantation (LT) has become an established treatment for patients with end-stage liver disease. Moreover, recently developed antihepatitis C virus (HCV) drugs may enable the elimination of this virus and reduce the frequency of HCV-associated events after LT. However, various post-LT complications do occur, including liver steatosis, which is commonly observed and can affect patient outcome. [1] [2] [3] A previous genome-wide association study described several single nucleotide polymorphisms (SNPs) that affect the pathophysiology of patients with chronic liver disease. 4, 5 Moreover, in a separate genome-wide association study, SNPs in the PNPLA3 gene were identified as predictors of non-alcoholic fatty liver disease (NAFLD) severity, 6 and the G allele of the rs738409 PNPLA3 SNP is reported to be a risk factor for the development of fibrosis and hepatocellular carcinoma in this disease. 7, 8 A number of studies based in North America and Europe have shown recipient PNPLA3 rs738409 genotype to be associated with liver steatosis following LT. 9 Furthermore, Dunn et al. reported that post-LT steatosis in recipients infected with HCV is associated with donor rs738409 genotype. 10 However, few studies of steatosis after LT have been undertaken in Asia. In the present investigation, we aimed to clarify the significance of PNPLA3 rs738409 genotype as a risk factor in liver steatosis or non-alcoholic steatohepatitis (NASH) after living-donor LT for chronic hepatitis C (CHC).
METHODS
F
ORTY-THREE LT RECIPIENTS infected with HCV were enrolled in this study. Eight of these patients had received interferon therapy before LT, but none showed clearance of HCV RNA prior to surgery. Twenty-one patients received antiviral therapy, 6 (28%) of whom achieved a sustained virologic response. Table 1 
Single nucleotide polymorphism genotyping
Recipient and donor genomic DNA was extracted from peripheral blood mononuclear cells. PNPLA3 rs738409 SNP genotypes were detected using TaqMan probes (Life Technologies Japan, Tokyo, Japan) according to the manufacturer's protocol.
Assessment of liver histopathology and steatosis
Patients underwent ultrasound-guided liver biopsies 1 year after LT and yearly thereafter, or when abnormal liver enzyme levels were detected. Donor steatosis was assessed using time-zero biopsies. Biopsy specimens were fixed in 10% formalin, embedded in paraffin, cut into 4-μm sections, and exposed to hematoxylin and eosin and azan staining. All liver tissue specimens were evaluated by two pathologists blinded to the clinical condition of the patient. Steatosis was defined as a steatotic hepatocyte presence ≥5%, and NASH as an NAFLD activity score ≥5.
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Statistical analysis
Univariate analysis (χ 2 -test or t-test) was undertaken to evaluate each factor. Those identified as significant were then subjected to multivariate analysis. Kaplan-Meier curves were generated and compared using the log-rank test. All analyses were carried out using SPSS Statistics version 20.0 (IBM, Armonk, NY, USA).
RESULTS
PNPLA3 genotype frequencies among donors and recipients
T HE DISTRIBUTIONS OF
PNPLA3 alleles were consistent with the Hardy equilibrium among donors and recipients. The frequency of the rs738409 G allele was 84% and 67% among recipients and donors, respectively. The GG genotype of this SNP, a steatosis risk factor, was carried by 13 recipients and 10 donors. Donor steatosis was observed in 0, 8, and 7 of the donors carrying the CC, CG, and GG alleles, respectively.
Risk factors in steatosis development following LT
Graft steatosis following LT was observed in 13 of the 43 patients (30%) included in this study, and NASH was diagnosed in 3 cases (7%). Among the 13 patients with steatosis, the level of steatosis was 5-33% in 6 cases, and 31-65% in the remaining 7. One patient showed no evidence of inflammation, 7 showed grade 1 inflammation, and 5 showed grade 2 inflammation. Additionally, 4 of the 13 patients showed grade 1 ballooning and 1 patient showed grade 2 ballooning; the remaining 8 patients showed no evidence of ballooning. Two patients showed no fibrosis; 4, 5, and 2 patients presented with stage 1, 2, and 3 fibrosis, respectively. Concerning recipient characteristics, we detected a significant correlation between the levels of total cholesterol at liver biopsy and development of steatosis. In contrast, no significant correlation between this condition and age, sex, body mass index, Child-Pugh score, total cholesterol, or triglyceride levels were detected (Table 2) .
Association between PNPLA3 and steatosis after LT Among the 13 recipients that developed steatosis, 2, 5, and 6 harbored the CC, CG, and GG rs738409 genotype, respectively. Among the non-steatosis group, these genotypes were present in 5, 18, and 7 patients, respectively. However, these differences were not statistically significant. Conversely, there were significant differences (P ≤ 0.05) in the frequencies of the CC, CG, and GG genotypes between the donors in the steatosis group (1, 5, and 7, respectively) and non-steatosis group (12, 14, and 4, respectively).
Steatosis was evident in 28, 22, and 46% of the recipients carrying the CC, CG, and GG rs738409 genotypes, respectively, although these differences were not statistically significant. However, steatosis was observed in 8, 26, and 60% of patients with transplants from donors of the CC, CG, and GG genotypes, respectively. Compared to the CC and CG donor rs738409 genotypes, the frequency of steatosis associated with transplants donated by GG carriers was significantly higher (P = 0.01) (Fig. 1) . Notably, all patients with NASH (3 cases) had received transplants from donors of the GG genotype. Multivariate analysis revealed that only the donor rs738409 genotype comprised a significant predictor for steatosis after LT (odds ratio = 1.27 [1.032-1.56]; P = 0.025). Moreover, the average time to steatosis differed significantly according to donor, but not recipient, rs738409 genotype (GG, 4.27 ± 1.09 years; GC and CC, 9.97 ± 0.890 years; P = 0.002) (Fig. 2) .
DISCUSSION
I
N THE PRESENT work, PNPLA3 genotype was found to be a risk factor for steatosis in NAFLD patients for the first time. In a previous Japanese cohort study, this factor CyA, cyclosporine; PSL, prednisolone; TAC, tacrolimus; T-cho, total-cholesterol; TG, triglyceride. Figure 1 Association between PNPLA3 and steatosis after liver transplantation in Japanese patients with chronic hepatitis C. The frequency of steatosis associated with transplant was not statistically linked to recipient rs738409 genotype. However, that associated with transplants donated by GG carriers was significantly higher than among patients receiving transplants from CC and CG carriers (P = 0.01). NS, not significant.
was also reported to confer risk of steatosis and progression of NASH and fibrosis.
12,13
Here, the PNPLA3 rs738409 GG donor genotype was established as a risk factor for liver steatosis following LT. In contrast, Finkenstedt et al. reported this same variant to be a post-LT liver steatosis risk factor when present among recipients, but not donors. 9 This discrepancy might be attributed to differences in genotype distribution between our Japanese cohort and that of this previous study, which focused on a Caucasian population. The GG genotype was carried by only 7% of donors in previously reported Caucasian cohorts, 6,9 whereas in our study, this figure was 23%. Our data are, however, consistent with those of prior investigations involving large Japanese cohorts. 12, 13 Therefore, the frequency of the PNPLA3 rs738409 GG genotype in the Japanese population is high compared to that among Caucasians.
Interestingly, all 3 patients with NASH had received tissue from donors of the GG genotype. Kawaguchi et al. showed this PNPLA3 genotype to be strongly associated with progression of NASH in Japanese patients. 12, 13 Our results concerning NASH after LT are thus compatible with the findings of this study. In addition, as mentioned above, Dunn et al. associated rs738409 donor genotype with HCV patient outcome post-LT. 10 Had the follow-up time of our study been longer, PNPLA3 genotype may have been found to be associated with NASH following LT.
In Japan, living-donor LT prevails due to the extreme shortage of deceased donor organs. Recipients and donors are usually blood relatives; therefore, genotype might affect steatosis after LT.
In this study, the average time to liver steatosis after LT was 2.71 ± 1.68 years, a relatively short period. Following LT, the use of immunosuppressive drugs and drastic improvements in nutrition may encourage the development of this condition. Importantly, time to liver steatosis post-LT in patients of the GG donor group was shorter than that observed among those of the CC or GC donor group. In conclusion, for LT involving donors of the rs738409 GG genotype, grafts should be carefully monitored for steatosis by regular ultrasonography and biopsy.
Regarding non-genetic influences, previous studies have proposed that recipient age, post-LT weight gain, immunosuppressive drugs, and non-viral cirrhosis are risk factors for liver steatosis after LT. 2, 3, [14] [15] [16] However, in our investigation, variables other than rs738409 donor genotype did not differ between the steatosis and non-steatosis groups, perhaps as only Japanese patients with HCV were included.
The present work had certain limitations. For instance, it comprised a single-center study with a small sample size. To validate our conclusions, a large multicenter investigation is needed. In addition, only patients with CHC were considered. Individuals suffering liver failure due to other causes, including non-viral cirrhosis, should be enrolled in future studies.
In summary, we clarified that donor, but not recipient, PNPLA3 rs738409 genotype is a significant risk factor for liver steatosis subsequent to LT for CHC. For transplants involving donors carrying the GG genotype of this variant, clinicians should carefully evaluate liver steatosis by ultrasonography and histology.
